Cargando…
Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds
The transcription factor FOXM1 is upregulated and overexpressed in aggressive, therapy-resistant forms of hormone receptor-positive and triple negative breast cancers, and is associated with less good patient survival. FOXM1 signaling is also a key driver in many other cancers. Here, we identify a n...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884575/ https://www.ncbi.nlm.nih.gov/pubmed/31815181 http://dx.doi.org/10.1038/s41523-019-0141-7 |
_version_ | 1783474578792644608 |
---|---|
author | Ziegler, Yvonne Laws, Mary J. Sanabria Guillen, Valeria Kim, Sung Hoon Dey, Parama Smith, Brandi P. Gong, Ping Bindman, Noah Zhao, Yuechao Carlson, Kathryn Yasuda, Mayuri A. Singh, Divya Li, Zhong El-Ashry, Dorraya Madak-Erdogan, Zeynep Katzenellenbogen, John A. Katzenellenbogen, Benita S. |
author_facet | Ziegler, Yvonne Laws, Mary J. Sanabria Guillen, Valeria Kim, Sung Hoon Dey, Parama Smith, Brandi P. Gong, Ping Bindman, Noah Zhao, Yuechao Carlson, Kathryn Yasuda, Mayuri A. Singh, Divya Li, Zhong El-Ashry, Dorraya Madak-Erdogan, Zeynep Katzenellenbogen, John A. Katzenellenbogen, Benita S. |
author_sort | Ziegler, Yvonne |
collection | PubMed |
description | The transcription factor FOXM1 is upregulated and overexpressed in aggressive, therapy-resistant forms of hormone receptor-positive and triple negative breast cancers, and is associated with less good patient survival. FOXM1 signaling is also a key driver in many other cancers. Here, we identify a new class of compounds effective in suppressing FOXM1 activity in breast cancers, and displaying good potency for antitumor efficacy. The compounds bind directly to FOXM1 and alter its proteolytic sensitivity, reduce the cellular level of FOXM1 protein by a proteasome- dependent process, and suppress breast cancer cell proliferation and cell cycle progression and increase apoptosis. RNA-seq and gene set enrichment analyses indicate that the compounds decrease expression of FOXM1-regulated genes and suppress gene ontologies under FOXM1 regulation. Several compounds have favorable pharmacokinetic properties and show good tumor suppression in preclinical breast tumor models. These compounds may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1. |
format | Online Article Text |
id | pubmed-6884575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-68845752019-12-06 Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds Ziegler, Yvonne Laws, Mary J. Sanabria Guillen, Valeria Kim, Sung Hoon Dey, Parama Smith, Brandi P. Gong, Ping Bindman, Noah Zhao, Yuechao Carlson, Kathryn Yasuda, Mayuri A. Singh, Divya Li, Zhong El-Ashry, Dorraya Madak-Erdogan, Zeynep Katzenellenbogen, John A. Katzenellenbogen, Benita S. NPJ Breast Cancer Article The transcription factor FOXM1 is upregulated and overexpressed in aggressive, therapy-resistant forms of hormone receptor-positive and triple negative breast cancers, and is associated with less good patient survival. FOXM1 signaling is also a key driver in many other cancers. Here, we identify a new class of compounds effective in suppressing FOXM1 activity in breast cancers, and displaying good potency for antitumor efficacy. The compounds bind directly to FOXM1 and alter its proteolytic sensitivity, reduce the cellular level of FOXM1 protein by a proteasome- dependent process, and suppress breast cancer cell proliferation and cell cycle progression and increase apoptosis. RNA-seq and gene set enrichment analyses indicate that the compounds decrease expression of FOXM1-regulated genes and suppress gene ontologies under FOXM1 regulation. Several compounds have favorable pharmacokinetic properties and show good tumor suppression in preclinical breast tumor models. These compounds may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1. Nature Publishing Group UK 2019-11-29 /pmc/articles/PMC6884575/ /pubmed/31815181 http://dx.doi.org/10.1038/s41523-019-0141-7 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Ziegler, Yvonne Laws, Mary J. Sanabria Guillen, Valeria Kim, Sung Hoon Dey, Parama Smith, Brandi P. Gong, Ping Bindman, Noah Zhao, Yuechao Carlson, Kathryn Yasuda, Mayuri A. Singh, Divya Li, Zhong El-Ashry, Dorraya Madak-Erdogan, Zeynep Katzenellenbogen, John A. Katzenellenbogen, Benita S. Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
title | Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
title_full | Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
title_fullStr | Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
title_full_unstemmed | Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
title_short | Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
title_sort | suppression of foxm1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884575/ https://www.ncbi.nlm.nih.gov/pubmed/31815181 http://dx.doi.org/10.1038/s41523-019-0141-7 |
work_keys_str_mv | AT ziegleryvonne suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT lawsmaryj suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT sanabriaguillenvaleria suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT kimsunghoon suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT deyparama suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT smithbrandip suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT gongping suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT bindmannoah suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT zhaoyuechao suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT carlsonkathryn suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT yasudamayuria suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT singhdivya suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT lizhong suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT elashrydorraya suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT madakerdoganzeynep suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT katzenellenbogenjohna suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds AT katzenellenbogenbenitas suppressionoffoxm1activitiesandbreastcancergrowthinvitroandinvivobyanewclassofcompounds |